The Solidarity trial provides simplified procedures to enable even overloaded hospitals to participate, with no paperwork required. More than 80 countries are working together to find an effective therapeutics as soon as possible through the trial. Therefore, Solidarity trial will reduce the time taken by 80%.
Trial is conducted on COVID-19 patients in the Chicago hospital with Gilead Sciences' antiviral medicine remdesivir.
A new public health tool dubbed World Without COVID was launched with the aim of connecting patients to coronavirus clinical trials across the country.
Fujifilm is testing up production of its antiviral treatment favipiravir for COVID-19. Let us tell you that phase III clinical trials are ongoing in Japan, and the government has ordered 2 million treatment courses. In the US, Fujifilm started Phase II trials. Fujifilm sells Favipiravir under the brand name Avigan and it has been approved by Japan since 2014 to treat influenza and other viral strains that do not respond to other drugs.
Antiviral drugs stop the working of the virus from replicating or infecting cells. They include everything from complex biotechnology therapies to older generics. Examples of other antivirals include HIV drugs, treatments of hepatitis C, and the influenza treatment Tamiflu, etc.
Hydroxychloroquine and chloroquine are anti-malarial drugs that have been tested in other outbreaks and for COVID-19 also.
In Convalescent Plasma or Plasma Therapy the blood of the recovered person as it is rich in antibodies is used to treat other sick people. Here convalescent plasma is the liquid part of the blood from the recovered patients of COVID-19
The liquid part of the blood is plasma. It is made up of large water and proteins. It provides a medium for RBC, WBC and platelets to circulate through the body. And it also consists of antibodies.
Convalescent Plasma Therapy was used for the Ebola virus and other coronavirus diseases like SARS and MERS.
Novavax's vaccine is meant to create antibodies that block a protein "spike" that the virus uses to infect its host. It has selected its vaccine candidate in April after seeing a strong immune response in animal testing.